

One step at a time to phase-by-phase wound care



curea P2 planned
introduction from the
4th quarter of 2011
curea P3 planned
introduction in 2012


Who we are

curea medical GmbH located in Berlingerode and Steinfurt is a competent partner in the medical care sector. We use state-of-the-art technology and comply with the most stringent of hygiene requirements, from the development stage right through to the packaging of our products. curea P1 wound dressings are available in many different sizes and packs.

SuperCore®: Clean, barrier-free absorbency



SuperCore® airlaids are made from clean, extremely absorbent cellulose-based material. Due to their patented manufacturing technology, no form of adhesive or binding agent is required. Thanks to special thermo-mechanic fibre connectors, SuperCore®, unlike conventional airlaids, displays impressive absorbency and excellent fluid dispersion. By dispensing with non-absorbent components, SuperCore® products have up to 30% more absorbency than conventional airlaids.



Conventional airlaids
Forming a grid-like barrier, adhesives prevent the effective absorption of fluids in conventional airlaids.



SuperCore®
Fluids are freely and swiftly absorbed by SuperCore® since no adhesives or binding agents are used.

adhesives- and binder-free

What motivates us

Progress and improving medical care – these principles form the basis of our company and our products. Our core competence lies in the development and manufacture of highly absorbent materials – an indication of considerable and, occasionally, even vital significance in various medical treatment areas, primarily wound management.

What we do

SuperCore®, the successful, patented airlaid with no adhesives or binding agents, gives P1 wound dressings – the first curea medical-Product to be launched on the market – an extremely high absorption and retention capacity. SuperCore® technology was developed and patented by McAirLaid's, the parent company of curea medical GmbH. All curea medical products thus possess impressive properties that are greatly appreciated by individual patients and medical staff alike.

What we offer

As a subsidiary of McAirLaid's, one of the leading European companies in the specialised non-woven segment, curea medical GmbH can draw on many years' successful experience in medical care – especially wound management. As the developer, producer and supplier of highly absorbent wound dressings with the patented SuperCore® airlaid, McAirLaid's has set a precedent in state-of-the-art wound management.


Who we are

curea medical GmbH located in Berlingerode and Steinfurt is a competent partner in the medical care sector. We use state-of-the-art technology and comply with the most stringent of hygiene requirements, from the development stage right through to the packaging of our products. curea P1 wound dressings are available in many different sizes and packs.

SuperCore®: Clean, barrier-free absorbency



SuperCore® airlaids are made from clean, extremely absorbent cellulose-based material. Due to their patented manufacturing technology, no form of adhesive or binding agent is required. Thanks to special thermo-mechanic fibre connectors, SuperCore®, unlike conventional airlaids, displays impressive absorbency and excellent fluid dispersion. By dispensing with non-absorbent components, SuperCore® products have up to 30% more absorbency than conventional airlaids.



Conventional airlaids
Forming a grid-like barrier, adhesives prevent the effective absorption of fluids in conventional airlaids.



SuperCore®
Fluids are freely and swiftly absorbed by SuperCore® since no adhesives or binding agents are used.

adhesives- and binder-free

What motivates us

Progress and improving medical care – these principles form the basis of our company and our products. Our core competence lies in the development and manufacture of highly absorbent materials – an indication of considerable and, occasionally, even vital significance in various medical treatment areas, primarily wound management.

What we do

SuperCore®, the successful, patented airlaid with no adhesives or binding agents, gives P1 wound dressings – the first curea medical-Product to be launched on the market – an extremely high absorption and retention capacity. SuperCore® technology was developed and patented by McAirLaid's, the parent company of curea medical GmbH. All curea medical products thus possess impressive properties that are greatly appreciated by individual patients and medical staff alike.

What we offer

As a subsidiary of McAirLaid's, one of the leading European companies in the specialised non-woven segment, curea medical GmbH can draw on many years' successful experience in medical care – especially wound management. As the developer, producer and supplier of highly absorbent wound dressings with the patented SuperCore® airlaid, McAirLaid's has set a precedent in state-of-the-art wound management.

The curea P product group: Staged wound management for an extraordinary treatment outcome

Modern wound management requires modern solutions. This is especially true for the treatment of chronic wounds – a sector that is frequently referred to under the key words, "Problem wounds".

Thanks to its successful, patented SuperCore® airlaid technology* coupled with a state-of-the-art manufacturing process, the curea P product group offers a staged response. With its impressive absorptive capacity and material composition that is gentle on both the skin and wounds, curea P1 presents a combination of remarkable properties.

curea P1 – use in the exudation phase

The curea P1 wound dressing is especially designed for the exudation phase. By virtue of its remarkable absorbency, curea P1 even cleans highly exuding wounds and creates a well-balanced wound climate. Wounds are thus given a longer resting phase to promote endogenous wound-healing mechanisms.

curea P2 – use in the granulation phase

[planned introduction from the 4th quarter of 2011]
Following a completed test phase, the curea P2 wound dressing will possess an absorption capacity that is optimised for the granulation phase together with a three-dimensional wound-side surface with special capillary structures in order to prevent wound adhesion.

curea P3 – use in the regeneration phase

[planned introduction in 2012]
The curea P3 wound dressing, which is currently at the development stage, will form the third step in the staged wound management process. Based on curea P1 and P2, it is intended to promote the healing process during the regeneration phase in particular, and thus promote complete wound healing.



curea P2 planned
introduction from the
4th quarter of 2011
curea P3 planned
introduction in 2012

* Patent of McAirLaid's – the parent company of curea medical GmbH



curea P1 – a tailor-made size to suit every wound



curea P1 wound dressings are available in various sizes and packing units.

Size*	Item No./10 pcs	Item No./25 pcs	Item No./50 pcs
7,5 x 7,5 cm	P1-075075-10	P1-075075-25	P1-075075-50
10 x 10 cm	P1-100100-10	P1-100100-25	P1-100100-50
10 x 20 cm	P1-100200-10	P1-100200-25	P1-100200-50
10 x 30 cm	P1-100300-10	P1-100300-25	P1-100300-50
20 x 20 cm	P1-200200-10	P1-200200-25	P1-200200-50
20 x 30 cm	P1-200300-10	P1-200300-25	P1-200300-50
12 x 12 cm drain	—	P1-100100D-25	P1-100100D-50

* External dimensions